CRV-101 Vaccine for Shingles

Recruiting in Palo Alto (17 mi)

+11 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Curevo Inc

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial tests a new shingles vaccine called CRV-101 in adults aged 50 and older. The vaccine aims to boost the immune system to prevent shingles. Participants receive two injections and are monitored for safety and effectiveness.

Eligibility Criteria

Adults aged 50 and older who are healthy, have completed a COVID-19 vaccine series at least 30 days prior to enrollment, and can give informed consent. They must not have had shingles vaccines before, no recent vaccinations or blood donations, no immune system issues or certain medications that affect immunity.

Inclusion Criteria

I am at least 50 years old and not pregnant.

I am 50 years old or older.

Exclusion Criteria

I am not on long-term immune system medications.

I do not have a fever or any sudden illness now.

I have been vaccinated against shingles or chickenpox.

I have an autoimmune disease or a condition that affects my immune system.

I have no history of severe allergies to vaccines or their components that would stop me from joining the study.

Participant Groups

The trial is testing the safety and effectiveness of different doses of CRV-101 vaccine with adjuvants against Shingrix for preventing herpes zoster (shingles). Participants will receive one of several dose combinations to compare responses.

6Treatment groups

Experimental Treatment

Active Control

Group I: Arm FExperimental Treatment1 Intervention

Investigational Vaccine

Group II: Arm EExperimental Treatment1 Intervention

Investigational Vaccine

Group III: Arm DExperimental Treatment1 Intervention

Investigational Vaccine

Group IV: Arm BExperimental Treatment1 Intervention

Investigational Vaccine

Group V: Arm AExperimental Treatment1 Intervention